A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD)
← catalyst calendarNCT07748403 · readout ≤ 834 d
Sponsored by Prime Medicine, Inc. (industry) · PRME — their whole pipeline →.
Phase
Phase 1/2
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
42estimated
Sites
1
Country
New Zealand
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Aug 2026 | estimated | When the study began enrolling |
| Primary completion | Nov 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Wilson Disease
- Wilson's Disease
- Wilsons Disease
Intervention
- Drug: PM577a
Primary outcome
what the primary-completion date above is the date OFSafety and tolerability of PM577a. Quantified by frequency and severity of treatment emergent adverse events (TEAEs).
measured Post-infusion through Week 48
Permalink · PRME's whole pipeline · Catalyst calendar · Every registered study · What changed